Weng Lian, Luo Yuxi, Luo Xiongjunjie, Yao Kaitao, Zhang Qian, Tan Junjie, Yin Yiran
Luzhou Longmatan District People's Hospital, Luzhou, China.
Department of Orthopedics, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Front Med (Lausanne). 2024 Aug 21;11:1401309. doi: 10.3389/fmed.2024.1401309. eCollection 2024.
Patients with Osteoarthritis (OA) often also suffer from Sleep Apnea Syndrome (SAS), and many scholars have started to notice this link, although the relationship between the two is still unclear. In this review, we aim to summarize the current literature on these two diseases, integrate evidence of the OA and OSA connection, explore and discuss their potential common mechanisms, and thus identify effective treatment methods for patients with both OA and SAS. Some shared characteristics of the two conditions have been identified, notably aging and obesity as mutual risk factors. Both diseases are associated with various biological processes or molecular pathways, including mitochondrial dysfunction, reactive oxygen species production, the NF-kB pathway, HIF, IL-6, and IL-8. SAS serves as a risk factor for OA, and conversely, OA may influence the progression of SAS. The effects of OA on SAS are underreported in the literature and require more investigation. To effectively manage these patients, timely intervention for SAS is necessary while treating OA, with weight reduction being a primary requirement, alongside combined treatments such as Continuous positive airway pressure (CPAP) and medications. Additionally, numerous studies in drug development are now aimed at inhibiting or clearing certain molecular pathways, including ROS, NF-KB, IL-6, and IL-8. Improving mitochondrial function might represent a viable new strategy, with further research into mitochondrial updates or transplants being essential.
骨关节炎(OA)患者常常也患有睡眠呼吸暂停综合征(SAS),尽管两者之间的关系仍不明确,但许多学者已开始注意到这种联系。在本综述中,我们旨在总结有关这两种疾病的当前文献,整合OA与OSA关联的证据,探索并讨论它们潜在的共同机制,从而确定针对同时患有OA和SAS的患者的有效治疗方法。已确定这两种病症的一些共同特征,尤其是衰老和肥胖作为共同的风险因素。这两种疾病都与各种生物学过程或分子途径相关,包括线粒体功能障碍、活性氧生成、NF-kB途径、HIF、IL-6和IL-8。SAS是OA的一个风险因素,反之,OA可能影响SAS的进展。OA对SAS的影响在文献中报道较少,需要更多研究。为了有效管理这些患者,在治疗OA时对SAS进行及时干预是必要的,减轻体重是首要要求,同时采用持续气道正压通气(CPAP)和药物等联合治疗。此外,目前药物研发中的众多研究旨在抑制或清除某些分子途径,包括ROS、NF-KB、IL-6和IL-8。改善线粒体功能可能是一种可行的新策略,对线粒体更新或移植进行进一步研究至关重要。